Author of

• 35916

  +

  P53 - Tumor Biology and Systems Biology - Basic and Translational Science - Misc. Topics (ID 213)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Tumor Biology and Systems Biology - Basic and Translational Science
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35921

    +

    P53.04 - GRgt, a Potent DPP4 Inhibitor, Improves of Combined Therapy with Immune Checkpoint Inhibitor (ICI) in Lung Cancer Immunotherapy (ID 2166)

    00:00 - 00:00  |  Presenting Author(s): Hyun Seock Shin
    • Abstract

    Introduction
    

    Lung cancer is the most common cause of death rate among all cancer related diseases. Although several drugs including immunotherapeutics (Immune Checkpoint Inhibitor; ICI) have been developed and used in recent years, the response rate is limited to about 25%. Therefore, many researchers have tried to combine treatment with other drugs to increase the therapeutic efficiency of ICI. Dipeptidyl peptidase 4 (DPP4) is a ubiquitously expressed transmembrane exopeptidase on the cell surface of many hematopoietic cells. According to some reports, DPP4 inhibitors have the ability to suppress tumor proliferation and tumor metastasis. GRgt, is a potent DPP4 inhibitor, it is chemically adamantane structure containing and modification. This study was performed to combined treatment of GRgt for improvement of therapeutic efficacy of ICI for lung cancer.

    Methods
    

    To confirm the cytotoxicity effect of GRgt, it was dose dependently treated in mouse Lewis lung carcinoma (LLC) cells, human lung carcinoma epithelial cell line (A549) and human lung carcinoma non-small cell lung cancer (H1299) then using water soluble tetrazolium (WST) assay as a similar DTT assay. TC-1 tumor-bearing mice were treated with either PD-1 antibody treatment group and/or GRgt treatment. Tumor sizes variation statistics were determined by student t-test.

    Results
    

    GRgt was shown to inhibit the cell proliferation in LLC, A549 and H1299 cells. The result that cell growth was reduced dose dependently of GRgt. TC-1 cell tumor bearing C57BL/6 mice, the size of tumors were reduced by alone GRgt treatment and significantly reduced co-treatment with mouse PD-1 antibody.

    Conclusion
    

    Our data provide evidence that GRgt might be a good co-treatment reagent for improves the efficacy of ICI in lung cancer treatment.